Zhitong Finance App News, Minimally Invasive Healthcare (00853) announced its annual results for the year ended December 31, 2023. The company's revenue was US$951 million, up 15.8% year on year; gross profit of US$532 million, up 6.0% year on year; loss attributable to the company's equity shareholders was US$478 million, up 9.4% year on year; basic loss per share.

During the reporting period, the Group continued to promote the steady development of various business compliance. Despite being affected by multiple adverse factors at home and abroad, thanks to the efficient promotion of product promotion and market development, the market share continued to grow rapidly. The Group achieved global business revenue of US$951 million, a significant increase of 15.8% over the same period of the previous year (excluding exchange rate influence). Among them, along with the brand effect brought about by matrix overseas, the revenue from the overseas business was US$57.1 million, a steady increase of 53.9% over the same period last year (excluding exchange rate influence); in the business sector, the Group's heart valve business, aortic artery and external markets Revenue from the vascular intervention business, neurological intervention business, and cardiovascular intervention business all achieved rapid growth, with increases of 32.5%, 32.2%, 21.6% and 14.7% respectively over the same period of the previous year (excluding exchange rate influence); benefiting from the rapid release of core products, surgical robot business revenue also increased sharply by 258.4% over the same period last year (excluding exchange rate influence), and the dominant market position continued to consolidate.

Focusing on improving operational efficiency, the Group has solidly promoted multiple fee control measures. During the reporting period, the total cost rates for R&D, management, and sales achieved a sharp drop of 22.1 percentage points over the same period last year. Facing various challenges, the Group actively implements strategic adjustments, strengthens resource focus, enhances resource collaboration, controls input and output, and controls the pace of investment in a value-oriented manner. During the reporting period, R&D expenses decreased by 9.6% year-on-year by adopting active cost control measures, prioritizing and focusing on core projects. The aim is to continuously optimize the human resources system and ensure that resource allocation matches strategic goals. During the reporting period, the Group's organizational structure was effectively streamlined, operational efficiency improved markedly, and management expenses decreased by 18.5% over the same period last year. In terms of marketing, the Group fully exploits the potential for information sharing and complementary advantages; at the same time, along with the steady increase in the number of products on the market, the advantages of the product portfolio are prominent, and its competitive strength is further enhanced; in the future, by continuing to strengthen the integration of channel resources and promote in-hospital exploration, admission efficiency and single-hospital output are expected to continue to grow steadily.